drugset / Trial / NCT06082102
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Timeline
- Start
- 2023-12-19
- Primary completion
- 2028-08-31
- Completion
- 2030-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lenalidomide | Other / unclassified | — | — |
| Subject | Orelabrutinib | Small molecule | — | — |
| Comparator | Rituximab | Monoclonal antibody | — | — |